ClinicalTrials.gg
CompletedNCT01667471Updated Nov 2, 2016Results posted

A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study

A Phase 3 interventional study of tocilizumab [RoActemra/Actemra] in Juvenile Idiopathic Arthritis, sponsored by Hoffmann-La Roche. Completed at 3 sites in Germany. Open to participants aged 9 Years to 18 Years. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
9 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing tocilizumab in Arthritis, Juvenile — 2 open to participants now, 2 under way, 1 of them phase 3. tocilizumab · Arthritis, Juvenile.

Enrollment
19th of 21
6 · median 52
Started
2012
with 3 others
Phase 3
12 of 21
1 open now
Registered
11th of 21
by date
Lead sponsor
12 of 21
Hoffmann-La Roche

Among the 21 studies testing tocilizumab in Arthritis, Juvenile, this one is the 19th largest by enrollment, is one of 4 that started in 2012, is one of 12 in phase 3, and was the 11th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

2 of the 21 studies testing tocilizumab in Arthritis, Juvenile are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 9 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing tocilizumab in Arthritis, Juvenile, or all of them as a file.
02

Study summary

This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 core study. Patients aged 9-18 years with at least JIA ACR30 clinical response to RoActemra/Actemra in the core study will be eligible to receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. Anticipated time on study treatment is 104 weeks.

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Browse trials for

04

Who can participate

Ages eligible
9 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 9 to 18 years of age who completed visit 33 (week 104) of WA19977 study with at least JIA ACR30 clinical response to RoActemra/Actemra relative to baseline in WA19977, with no AEs, SAEs or conditions that lead to unacceptable risk of continued treatment
  • Scheduled to receive first RoActemra/Actemra infusion in this study between 4 and 6 weeks after the last IV infusion in the core study
  • Females of and males with female partners of child-bearing potential must agree to use effective as defined by protocol

Exclusion criteria

Exclusion Criteria:

  • Patients with, according to investigator judgment, not satisfactory benefit from RoActemra/Actemra therapy within WA19977
  • Treatment with any agent since the last administration of study drug in the core study WA19977 or current participation in another clinical trial except WA19977
  • Patient developed any other rheumatic disease or overlap syndrome other than the permitted polyarticular-course JIA subsets: rheumatoid factor positive or negative JIA or extended oligoarticular JIA
  • Patient is pregnant , lactating, or intending to become pregnant during the study and up to 12 weeks after the last administration of study drug
  • Any significant concomitant disease or medical or surgical condition
  • History of significant allergic or infusion reactions to prior biologic therapy
  • Known current active acute, subacute, chronic or history of recurrent infection; patients suffering from ongoing active infections with Epstein Barr virus, herpes zoster or recurrent history of urinary tract infection can be included after the (acute) infection has been excluded or subsided
  • Positive for latent tuberculosis (TB)
  • Currently active asthma for which the patient has required the use of oral or parenteral for >/= 2 weeks within 6 months prior to entering the study
  • Inadequate hepatic, renal or bone marrow function
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    RoActemra/Actemra

    Drug: tocilizumab [RoActemra/Actemra]

Interventions

  • Drugtocilizumab [RoActemra/Actemra]

    Drug page: Tocilizumab

    8 mg/kg iv every 4 weeks, 104 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events of Special Interest and Study-Drug Related Adverse Events

    Adverse Events (AEs) and Serious Adverse Events (SAEs) were recorded from the first day of tocilizumab administration until 4 weeks after administration of the last dose of tocilizumab. AEs of special interest were Infections (including all opportunistic infections and non-serious infections as defined by those treated with IV anti-infectives), Myocardial infarction/Acute coronary syndrome, Gastrointestinal perforations and related events, Malignancies, Anaphylaxis/Hypersensitivity reactions, Demyelinating disorders, Stroke. Bleeding events, Hepatic events and Macrophage activation syndrome (MAS).

    Time frame: Baseline and every 4 weeks up to Week 76 and Final Follow-Up Visit (up to 82 weeks)

  2. Number of AEs of Special Interest and Study Drug Related AEs

    AEs and SAEs were recorded from the first day of tocilizumab administration until 4 weeks after administration of the last dose of tocilizumab.

    Time frame: Baseline and every 4 weeks up to Week 76 and Final Follow-Up Visit (up to 82 weeks)

Secondary outcomes

  1. Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30/50/70/90 by Visit

    The six JIA ACR components comprised of: 1) Physician's global assessment of disease activity, 2) Parent/Participant's global assessment of overall well-being, 3) Maximum number of joints with active arthritis, 4) Number of joints with limitation of movement, 5) Erythrocyte Sedimentation Rate (ESR) and/or C-reactive Protein (CRP), and 6) Childhood Health Assessment Questionnaire - Disease Index (CHAQ-DI). At an assessment visit, a JIA ACR30/50/70/90 response in comparison to Baseline was defined as: At least three of the six JIA ACR core components improving by at least 30 percent (%), 50%, 70%, or 90% respectively and no more than one of the remaining JIA ACR core components worsening by more than 30%.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72 and Final Follow-Up Visit (up to 82 weeks)

  2. Percentage of Participants With Inactive Disease by Visit

    A participant was defined to show inactive disease if all of the following criteria were applied: 1) No joints with active arthritis (no joints with swelling and no joints with lack of motion), 2) No fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA, 3) No active uveitis, 4) ESR and/or CRP within normal range, and 5) Physician's global assessment of disease activity equals (=) 0 millimeters (mm) on a Visual analog scale (VAS).

    Time frame: Baseline, Weeks 12, 24, 36, 48, 60, 72 and Final Follow-Up Visit (up to 82 weeks)

  3. Percentage of Participants Achieving Clinical Remission (CR) at Each Visit

    CR was defined as "clinical remission with medication (CRem)". A participant was in CR if inactive disease was observed for a minimum of 6 consecutive months.

    Time frame: Baseline, Screening, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76 and Final Follow-Up Visit (up to 82 weeks)

  4. Physicians Assessment of Global Activity (VAS)

    The participant's treating physician provided a rating of the participant's arthritis disease activity on a 0 to 100 mm horizontal scale. The extreme left end of the line, score 0 represented 'arthritis inactive' (ie, symptom-free and no arthritis symptoms) and the extreme right end score 100 represented 'arthritis very active'. A higher score indicated more disease activity.

    Time frame: Baseline, Weeks 12, 24, 28, 32, 36, 48, 60, 72 and Final Follow-Up Visit (up to 82 weeks)

  5. Parent or Participant's Assessment of Global Activity (VAS)

    The participant or parent/guardian, as appropriate, provided a rating of the participant's well-being on a 0 to 100 mm horizontal scale. The extreme left end of the line Score 0 represented 'very well' (ie, symptom-free and no arthritis disease activity) and the extreme right end score 100 represented 'very poor' (ie, maximum arthritis disease activity). A higher score indicated poorer well-being.

    Time frame: Baseline, Weeks 12, 24, 28, 32, 36, 48, 60, 72 and Final Follow-Up Visit (up to 82 weeks)

  6. Number of Joints With Active Arthritis

    Joints with active arthritis were defined as joints with swelling or pain and limited of motion. The maximum number of joints with active arthritis was 71.The joint assessment was performed by an independent assessor who was not the treating physician and who was blinded to all other aspects of the participant's efficacy and safety data.

    Time frame: Baseline, Weeks 12, 24, 28, 32, 36, 48, 60, 72 and Final Follow-Up Visit (up to 82 weeks)

  7. Number of Joints With Lack of Motion

    Joints with lack of movement were assessed. The maximum number of joints with lack of movement was 67. The joint assessment was performed by an independent assessor who was not the treating physician and who was blinded to all other aspects of the participant's efficacy and safety data.

    Time frame: Baseline, Weeks 12, 24, 28, 32, 36, 48, 60, 72 and Final Follow-Up Visit (up to 82 weeks)

  8. Erythrocyte Sedimentation Rate

    ESR is a marker of inflammation and was measured as millimeters per hour (mm/h). Healthy individuals have low ESR. Higher ESR indicate inflammation.

    Time frame: Baseline, Weeks 4, 8,12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76 and Final Follow-Up Visit (up to 82 weeks)

  9. CHAQ-DI Score

    The CHAQ-DI questionnaire consisted of 30 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain had at least two component questions and if applicable to the participant there were four possible responses (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do). The CHAQ-DI score is the sum of the domain scores divided by the number of domains that have a non-missing score. This overall score ranges from 0 (best) to 3 (worst).

    Time frame: Baseline, Weeks 12, 24, 28, 32, 36, 48, 60, 72, and Final Follow-Up Visit (up to 82 weeks)

  10. Parent or Participant's Assessment of Pain (VAS)

    Parents or participants rated participant's pain by placing a horizontal line on a VAS of 0 (no pain)- 100 mm (severe pain).

    Time frame: Baseline, Weeks 12, 24, 28, 32, 36, 48, 60, 72, and Final Follow-Up Visit (up to 82 weeks)

  11. CRP Levels

    CRP an acute phase protein, is a marker of inflammation. CRP was measured as milligrams per deciliter (mg/dL).

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76 and Final Follow-Up Follow-Up Visit (up to 82 weeks)

07

Results

Posted Oct 2, 2015

Participant flow

Participant flow — Overall Study
MilestoneTocilizumab 8 mg/kg
Started7
Completed7
Not completed0

Outcome measures

PrimaryNumber of Participants With Adverse Events of Special Interest and Study-Drug Related Adverse Events

Adverse Events (AEs) and Serious Adverse Events (SAEs) were recorded from the first day of tocilizumab administration until 4 weeks after administration of the last dose of tocilizumab. AEs of special interest were Infections (including all opportunistic infections and non-serious infections as defined by those treated with IV anti-infectives), Myocardial infarction/Acute coronary syndrome, Gastrointestinal perforations and related events, Malignancies, Anaphylaxis/Hypersensitivity reactions, Demyelinating disorders, Stroke. Bleeding events, Hepatic events and Macrophage activation syndrome (MAS).

Time frame:
Baseline and every 4 weeks up to Week 76 and Final Follow-Up Visit (up to 82 weeks)
Reported as:
Number · participants
Number of Participants With Adverse Events of Special Interest and Study-Drug Related Adverse Events
participantsTocilizumab
Drug related AEs6
Drug related SAEs0
AEs of special interest1
Drug-related AEs of special interest1
SecondaryPercentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30/50/70/90 by Visit

The six JIA ACR components comprised of: 1) Physician's global assessment of disease activity, 2) Parent/Participant's global assessment of overall well-being, 3) Maximum number of joints with active arthritis, 4) Number of joints with limitation of movement, 5) Erythrocyte Sedimentation Rate (ESR) and/or C-reactive Protein (CRP), and 6) Childhood Health Assessment Questionnaire - Disease Index (CHAQ-DI). At an assessment visit, a JIA ACR30/50/70/90 response in comparison to Baseline was defined as: At least three of the six JIA ACR core components improving by at least 30 percent (%), 50%, 70%, or 90% respectively and no more than one of the remaining JIA ACR core components worsening by more than 30%.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 60, 72 and Final Follow-Up Visit (up to 82 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30/50/70/90 by Visit
percentage of participantsTocilizumab 8 mg/kg
Baseline JIA ACR30 (n=7)85.7
Week 12 JIA ACR30 (n=7)100.0
Week 24 JIA ACR30 (n=7)100.0
Week 36 JIA ACR30 (n=7)100.0
Week 48 JIA ACR30 (n=6)100.0
Week 60 JIA ACR30 (n=6)100.0
Week 72 JIA ACR30 (n=2)100.0
Follow-Up JIA ACR30 (n=7)100.0
Baseline JIA ACR50 (n=7)85.7
Week 12 JIA ACR50 (n=7)100.0
Week 24 JIA ACR50 (n=7)100.0
Week 36 JIA ACR50 (n=7)100.0
Week 48 JIA ACR50 (n=6)100.0
Week 60 JIA ACR50 (n=6)100.0
Week 72 JIA ACR50 (n=2)100.0
Follow-Up JIA ACR50 (n=7)100.0
Baseline JIA ACR70 (n=6)85.7
Week 12 JIA ACR70 (n=7)100.0
Week 24 JIA ACR70 (n=7)100.0
Week 36 JIA ACR70 (n=7)100.0
Week 48 JIA ACR70 (n=6)100.0
Week 60 JIA ACR70 (n=6)100.0
Week 72 JIA ACR70 (n=2)100.0
Follow-Up JIA ACR70 (n=7)100.0
Baseline JIA ACR90 (n=6)85.7
Week 12 JIA ACR90 (n=7)85.7
Week 24 JIA ACR90 (n=7)57.1
Week 36 JIA ACR90 (n=7)71.4
Week 48 JIA ACR90 (n=6)83.3
Week 60 JIA ACR90 (n=6)66.7
Week 72 JIA ACR90 (n=2)100.0
Follow-Up JIA ACR90 (n=7)85.7
PrimaryNumber of AEs of Special Interest and Study Drug Related AEs

AEs and SAEs were recorded from the first day of tocilizumab administration until 4 weeks after administration of the last dose of tocilizumab.

Time frame:
Baseline and every 4 weeks up to Week 76 and Final Follow-Up Visit (up to 82 weeks)
Reported as:
Number · adverse events
Number of AEs of Special Interest and Study Drug Related AEs
adverse eventsTocilizumab 8 mg/kg
Drug related AEs22
Drug related SAEs0
AEs of special interest2
Drug-related AEs of special interest2
SecondaryPercentage of Participants With Inactive Disease by Visit

A participant was defined to show inactive disease if all of the following criteria were applied: 1) No joints with active arthritis (no joints with swelling and no joints with lack of motion), 2) No fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA, 3) No active uveitis, 4) ESR and/or CRP within normal range, and 5) Physician's global assessment of disease activity equals (=) 0 millimeters (mm) on a Visual analog scale (VAS).

Time frame:
Baseline, Weeks 12, 24, 36, 48, 60, 72 and Final Follow-Up Visit (up to 82 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Inactive Disease by Visit
percentage of participantsTocilizumab 8 mg/kg
Baseline(n=7)57.1
Week 12 (n=7)42.9
Week 24 (n=7)14.3
Week 36 (n=7)42.9
Week 48 (n=6)16.7
Week 60 (n=6)33.3
Week 72 (n=2)50.0
Follow-Up (n=7)57.1
SecondaryPercentage of Participants Achieving Clinical Remission (CR) at Each Visit

CR was defined as "clinical remission with medication (CRem)". A participant was in CR if inactive disease was observed for a minimum of 6 consecutive months.

Time frame:
Baseline, Screening, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76 and Final Follow-Up Visit (up to 82 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Remission (CR) at Each Visit
percentage of participantsTocilizumab 8 mg/kg
Baseline (n=7)0.0
Screening (n=7)0.0
Week 4 (n=7)0.0
Week 8 (n=7)0.0
Week 12 (n=7)0.0
Week 16 (n=7)0.0
Week 20 (n=7)0.0
Week 24 (n=7)0.0
Week 28 (n=7)14.3
Week 32 (n=7)14.3
Week 36 (n=7)14.3
Week 40 (n=6)16.7
Week 44 (n=6)16.7
Week 48 (n=6)16.7
Week 52 (n=6)16.7
Week 56 (n=6)16.7
Week 60 (n=6)0.0
Week 64 (n=5)0.0
Week 68 (n=3)0.0
Week 72 (n=2)0.0
Week 76 (n=1)0.0
Follow-Up (n=7)0.0
SecondaryPhysicians Assessment of Global Activity (VAS)

The participant's treating physician provided a rating of the participant's arthritis disease activity on a 0 to 100 mm horizontal scale. The extreme left end of the line, score 0 represented 'arthritis inactive' (ie, symptom-free and no arthritis symptoms) and the extreme right end score 100 represented 'arthritis very active'. A higher score indicated more disease activity.

Time frame:
Baseline, Weeks 12, 24, 28, 32, 36, 48, 60, 72 and Final Follow-Up Visit (up to 82 weeks)
Reported as:
Mean · mm
Physicians Assessment of Global Activity (VAS)
mmTocilizumab 8 mg/kg
Baseline (n=7)12.0 ± 30.4
Week 12 (n=7)2.3 ± 2.9
Week 24 (n=7)5.4 ± 6.1
Week 28 (n=1)1.0 ± 0.0
Week 32 (n=2)29.0 ± 8.5
Week 36 (n=7)5.0 ± 7.9
Week 48 (n=6)5.7 ± 8.2
Week 60 (n=6)5.7 ± 8.7
Week 72 (n=2)1.0 ± 1.4
Follow-Up (n=7)5.0 ± 8.7
SecondaryParent or Participant's Assessment of Global Activity (VAS)

The participant or parent/guardian, as appropriate, provided a rating of the participant's well-being on a 0 to 100 mm horizontal scale. The extreme left end of the line Score 0 represented 'very well' (ie, symptom-free and no arthritis disease activity) and the extreme right end score 100 represented 'very poor' (ie, maximum arthritis disease activity). A higher score indicated poorer well-being.

Time frame:
Baseline, Weeks 12, 24, 28, 32, 36, 48, 60, 72 and Final Follow-Up Visit (up to 82 weeks)
Reported as:
Mean · mm
Parent or Participant's Assessment of Global Activity (VAS)
mmTocilizumab 8 mg/kg
Baseline (n=7)10.1 ± 20.0
Week 12 (n=7)7.1 ± 8.1
Week 24 (n=7)16.4 ± 19.9
Week 28 (n=1)1.0 ± 0.0
Week 32 (n=2)22.5 ± 24.7
Week 36 (n=7)12.1 ± 18.4
Week 48 (n=6)11.7 ± 13.9
Week 60 (n=6)10.2 ± 13.8
Week 72 (n=2)3.5 ± 4.9
Follow-Up (n=7)9.7 ± 16.0
SecondaryNumber of Joints With Active Arthritis

Joints with active arthritis were defined as joints with swelling or pain and limited of motion. The maximum number of joints with active arthritis was 71.The joint assessment was performed by an independent assessor who was not the treating physician and who was blinded to all other aspects of the participant's efficacy and safety data.

Time frame:
Baseline, Weeks 12, 24, 28, 32, 36, 48, 60, 72 and Final Follow-Up Visit (up to 82 weeks)
Reported as:
Mean · joints
Number of Joints With Active Arthritis
jointsTocilizumab 8 mg/kg
Baseline (n=7)0.9 ± 2.3
Week 12 (n=7)0.3 ± 0.8
Week 24 (n=7)1.0 ± 2.6
Week 28 (n=1)1.0 ± 0.0
Week 32 (n=2)1.5 ± 0.7
Week 36 (n=7)1.1 ± 2.2
Week 48 (n=6)0.0 ± 0.0
Week 60 (n=6)0.3 ± 0.8
Week 72 (n=2)0.0 ± 0.0
Follow-Up (n=7)0.3 ± 0.8
SecondaryNumber of Joints With Lack of Motion

Joints with lack of movement were assessed. The maximum number of joints with lack of movement was 67. The joint assessment was performed by an independent assessor who was not the treating physician and who was blinded to all other aspects of the participant's efficacy and safety data.

Time frame:
Baseline, Weeks 12, 24, 28, 32, 36, 48, 60, 72 and Final Follow-Up Visit (up to 82 weeks)
Reported as:
Mean · joints
Number of Joints With Lack of Motion
jointsTocilizumab 8 mg/kg
Baseline (n=7)1.4 ± 2.7
Week 12 (n=7)2.6 ± 5.1
Week 24 (n=7)2.4 ± 3.2
Week 28 (n=1)1.0 ± 0.0
Week 32 (n=2)5.5 ± 7.8
Week 36 (n=7)1.7 ± 2.4
Week 48 (n=6)2.7 ± 5.2
Week 60 (n=6)1.8 ± 3.0
Week 72 (n=2)0.0 ± 0.0
Follow-Up (n=7)2.9 ± 4.8
SecondaryErythrocyte Sedimentation Rate

ESR is a marker of inflammation and was measured as millimeters per hour (mm/h). Healthy individuals have low ESR. Higher ESR indicate inflammation.

Time frame:
Baseline, Weeks 4, 8,12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76 and Final Follow-Up Visit (up to 82 weeks)
Reported as:
Mean · mm/h
Erythrocyte Sedimentation Rate
mm/hTocilizumab 8 mg/kg
Baseline (n=7)4.9 ± 5.1
Week 4 (n=7)3.0 ± 1.9
Week 8 (n=7)2.9 ± 2.3
Week 12 (n=7)3.0 ± 2.0
Week 16 (n=7)8.6 ± 16.1
Week 20 (n=7)2.6 ± 0.8
Week 24 (n=7)2.7 ± 1.4
Week 28 (n=5)3.4 ± 3.1
Week 32 (n=7)4.3 ± 4.2
Week 36 (n=7)4.3 ± 2.5
Week 40 (n=6)2.0 ± 1.8
Week 44 (n=6)2.7 ± 1.5
Week 48 (n=6)3.8 ± 1.5
Week 52 (n=6)3.2 ± 3.6
Week 56 (n=6)2.3 ± 1.6
Week 60 (n=6)10.2 ± 12.7
Week 64 (n=5)3.2 ± 2.4
Week 68 (n=3)10.0 ± 7.2
Week 72 (n=2)4.5 ± 0.7
Week 76 (n=1)2.0 ± 0.0
Follow-Up (n=7)4.3 ± 2.8
SecondaryCHAQ-DI Score

The CHAQ-DI questionnaire consisted of 30 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain had at least two component questions and if applicable to the participant there were four possible responses (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do). The CHAQ-DI score is the sum of the domain scores divided by the number of domains that have a non-missing score. This overall score ranges from 0 (best) to 3 (worst).

Time frame:
Baseline, Weeks 12, 24, 28, 32, 36, 48, 60, 72, and Final Follow-Up Visit (up to 82 weeks)
Reported as:
Mean · score on a scale
CHAQ-DI Score
score on a scaleTocilizumab 8 mg/kg
Baseline (n=7)0.0 ± 0.0
Week 12 (n=7)0.04 ± 0.09
Week 24 (n=7)0.14 ± 0.20
Week 28 (n=1)0.00 ± 0.0
Week 32 (n=2)0.19 ± 0.27
Week 36 (n=7)0.13 ± 0.33
Week 48 (n=6)0.00 ± 0.00
Week 60 (n=6)0.21 ± 0.51
Week 72 (n=2)0.00 ± 0.00
Follow-Up (n=7)0.00 ± 0.00
SecondaryParent or Participant's Assessment of Pain (VAS)

Parents or participants rated participant's pain by placing a horizontal line on a VAS of 0 (no pain)- 100 mm (severe pain).

Time frame:
Baseline, Weeks 12, 24, 28, 32, 36, 48, 60, 72, and Final Follow-Up Visit (up to 82 weeks)
Reported as:
Mean · mm
Parent or Participant's Assessment of Pain (VAS)
mmTocilizumab 8 mg/kg
Baseline (n=7)10.9 ± 21.8
Week 12 (n=7)7.0 ± 10.0
Week 24 (n=7)13.7 ± 16.7
Week 28 (n=1)1.0 ± 0.0
Week 32 (n=2)28.5 ± 17.7
Week 36 (n=7)10.6 ± 15.9
Week 48 (n=6)12.3 ± 13.6
Week 60 (n=6)10.2 ± 13.8
Week 72 (n=2)4.0 ± 5.7
Follow-Up (n=7)9.9 ± 15.9
SecondaryCRP Levels

CRP an acute phase protein, is a marker of inflammation. CRP was measured as milligrams per deciliter (mg/dL).

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76 and Final Follow-Up Follow-Up Visit (up to 82 weeks)
Reported as:
Mean · mg/dL
CRP Levels
mg/dLTocilizumab 8 mg/kg
Baseline (n=7)0.03 ± 0.01
Week 4 (n=7)0.05 ± 0.07
Week 8 (n=7)0.02 ± 0.02
Week 12 (n=7)0.03 ± 0.01
Week 16 (n=7)0.23 ± 0.54
Week 20 (n=7)0.05 ± 0.07
Week 24 (n=7)0.03 ± 0.02
Week 28 (n=6)0.02 ± 0.02
Week 32 (n=7)0.03 ± 0.02
Week 36 (n=7)0.02 ± 0.02
Week 40 (n=6)0.03 ± 0.02
Week 44 (n=6)0.03 ± 0.02
Week 48 (n=6)0.03 ± 0.02
Week 52 (n=6)0.02 ± 0.02
Week 56 (n=6)0.03 ± 0.02
Week 60 (n=6)0.38 ± 0.90
Week 64 (n=5)0.03 ± 0.03
Week 68 (n=3)0.09 ± 0.10
Week 72 (n=2)0.04 ± 0.04
Week 76 (n=1)0.05 ± 0.0
Follow-Up (n=7)0.05 ± 0.06

Adverse events

Collected over Adverse events were collected from the date of screening until the final Follow-Up Visit (up to 82 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab 8 mg/kg—1/7 (14.3%)7/7 (100%)
Most frequent serious events
Most frequent serious events
EventTocilizumab 8 mg/kg
AppendicitisInfections and infestations1/7
Most frequent other events
Showing 10 of 44
Most frequent other events
EventTocilizumab 8 mg/kg
GastroenteritisInfections and infestations4/7
ArthralgiaMusculoskeletal and connective tissue disorders4/7
Upper respiratory tract infectionInfections and infestations3/7
Juvenile idiopathic arthritisMusculoskeletal and connective tissue disorders3/7
Abdominal painGastrointestinal disorders2/7
Abdominal pain upperGastrointestinal disorders2/7
NauseaGastrointestinal disorders2/7
NeutropeniaBlood and lymphatic system disorders1/7
Aortic valve incompetenceCardiac disorders1/7
Mitral valve incompetenceCardiac disorders1/7

Baseline characteristics

All participants who received at least one dose of study drug were included in the Safety Analysis Set.

Age, Continuous
Age, Continuous(years)Tocilizumab 8 mg/kg
Mean14.4 ± 3.2
Gender
Gender(Participants)Tocilizumab 8 mg/kg
Female6
Male1
08

Study locations

3 sites
  • Bremen, 28177, Germany
  • Frankfurt/Main, 60316, Germany
  • Sankt Augustin, 53757, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2012
First posted
Aug 17, 2012
Start
Jan 2012
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results first posted
Oct 2, 2015
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01667471
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 17, 2012
Start date
Jan 2012
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
Oct 2, 2015
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion